Clinical trials: Hypoplasia, Pulmonary
Hernia, Diaphragmatic, Hypertension, Pulmonary
Chronic Sildenafil for Severe Diaphragmatic Hernia
The purpose of this study is to test if sildenafil is effective in the treatment of infants with severe congenital diaphragmatic hernia (determined by the presence of prolonged pulmonary hypertension or prolonged oxygen…
- Conditions
- Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
- Trial name
- NCT00133679
- Testing
- sildenafil
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Francisco
Congenital Diaphragmatic Hernia, Fetal Surgery
Fetal Surgery for Moderate Left Sided Congenital Diaphragmatic Hernia.
Isolated Congenital Diaphragmatic Hernia (CDH) can be diagnosed in the prenatal period, and remains associated with a 30 % chance of perinatal death and morbidity mainly because of pulmonary hypoplasia and pulmonary hypertension.
- Conditions
- Congenital Diaphragmatic Hernia, Fetal Surgery, Pulmonary Hypoplasia
- Trial name
- TOTAL moderate (NCT00763737)
- Testing
- Fetoscopic Endoluminal Tracheal Occlusion
- Where
- 13 sites in United States, Australia and 8 more
- Volunteers
- 196 people
- Sponsor
- University Hospital, Gasthuisberg
Metastatic Pancreatic Ductal Adenocarcinoma
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02583477
- Testing
- MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Ductal Adenocarcinoma
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
- Trial name
- NCT02558894
- Testing
- MEDI4736 monotherapy, tremelimumab+MEDI4736
- Where
- 21 sites in United States, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Pancreatic Cancer
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
This Phase Ib dose escalation study will evaluate BTH1704, a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1, and Imprime PGG, a glucan contained in yeast that is essential in triggering a…
- Trial name
- PM-01 (NCT02132403)
- Testing
- BTH1704, IMPRIME PGG, Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Illinois Chicago